Skip to Main Content

++

Chapter 52. Benign Prostatic Hyperplasia

++
++
++

A uroselective α-adrenergic antagonist inhibits this α-adrenergic receptor in prostatic smooth muscle?

++
++
++

A. α1A

++
++

B. α1D

++
++

C. α1B

++
++

D. α2A

++
++

E. α2B

++
++
++

Use of a 5α-reductase inhibitor can be expected to reduce the volume of an enlarged prostate gland by this percentage.

++
++
++

A. 10

++
++

B. 20

++
++

C. 50

++
++

D. 75

++
++

E. 100

++
++
++

Use of an α-adrenergic antagonist or a 5 α-reductase inhibitor can be expected to have this clinical effect in patients with symptomatic BPH:

++
++
++

A. Decrease peak urinary flow rate

++
++

B. Increase postvoid residual urine volume

++
++

C. Increase detrusor relaxation

++
++

D. Improve bladder emptying

++
++

E. Increase urinary frequency

++
++
++

Which of these agent(s) has/have a low likelihood of causing cardiovascular adverse effects in a patient with BPH who also is receiving antihypertensives for essential hypertension?

+

1. Alfuzosin

+

2. Tamsulosin

+

3. Silodosin

++
++
++

A. 1 only

++
++

B. 2 only

++
++

C. 3 only

++
++

D. 1 and 3 only

++
++

E. 1, 2, and 3

++
++
++

Which one of the following statements about tadalafil’s use for LUTS is correct?

++
++
++

A. It should be dosed on demand or when needed.

++
++

B. It is indicated for patients with complications of BPH.

++
++

C. It works by causing relaxation of the detrusor muscle.

++
++

D. It produces an increase in peak urinary flow rate.

++
++

E. It reduces the AUA symptom score by at least 3 points.

++
++
++

The benefits of combination treatment with a 5α -reductase inhibitor and α-adrenergic antagonist for BPH includes all of the following except:

++
++
++

A. Increasing urinary flow rate

++
+...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.